1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Social Media Data Gains Prominence In Patient-Focused Drug Development

 
• By Brenda Sandburg

FDA guidances have provided ‘major step forward’ for use of social media data, Roche researcher notes. Agency staffer offers checklist for collecting patient experience data in this realm.

Social media
Comparnies are using social media in their patient-focused drug development programs • Source: Shutterstock

While the pharmaceutical industry has been waiting for more guidance from the US Food and Drug Administration on the use of social media to communicate drug information, the agency has provided advice on its utilization in another critical area: patient-focused drug development.

The FDA discusses the use of social media in two patient-focused drug development guidances, one on collecting input from patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Former CBER Director Peter Marks Brings Genetic Medicines Street Cred To Lilly

 
• By Jessica Merrill

FDA’s former CBER director is joining industry as senior VP of molecule discovery and head, infectious disease at Eli Lilly.

New US FDA Program Encouraging Domestic Manufacturing May Be ‘Very Selective’

 
• By Sarah Karlin-Smith

Pharmaceutical manufacturers encouraged the FDA to consider including expansions and modifications of existing US drug facilities in the PreCheck program.

US FDA Independence Questioned At CDC Oversight Hearing

 
• By Michael McCaughan

A Senate committee is investigating leadership changes at the US Centers for Disease Control and Prevention. While the primary focus is vaccine policy, the first hearing suggested the probe could raise questions about FDA independence.

Evita’s Mifepristone Approval Reignites Abortion Pill Controversy

 
• By Dave Wallace

An FDA approval of Evita Solutions' generic mifepristone 200mg tablets has reignited debate about the abortion pill, which Health and Human Services Secretary Robert F. Kennedy Jr. has indicated will be subject to a safety review.

More from Agency Leadership

New US FDA Program Encouraging Domestic Manufacturing May Be ‘Very Selective’

 
• By Sarah Karlin-Smith

Pharmaceutical manufacturers encouraged the FDA to consider including expansions and modifications of existing US drug facilities in the PreCheck program.

US FDA Independence Questioned At CDC Oversight Hearing

 
• By Michael McCaughan

A Senate committee is investigating leadership changes at the US Centers for Disease Control and Prevention. While the primary focus is vaccine policy, the first hearing suggested the probe could raise questions about FDA independence.

Evita’s Mifepristone Approval Reignites Abortion Pill Controversy

 
• By Dave Wallace

An FDA approval of Evita Solutions' generic mifepristone 200mg tablets has reignited debate about the abortion pill, which Health and Human Services Secretary Robert F. Kennedy Jr. has indicated will be subject to a safety review.